Furui Co.,Ltd(300049)

Search documents
福瑞股份收盘上涨3.04%,滚动市盈率110.92倍,总市值110.03亿元
Sou Hu Cai Jing· 2025-07-22 09:28
7月22日,福瑞股份今日收盘41.31元,上涨3.04%,滚动市盈率PE(当前股价与前四季度每股收益总和 的比值)达到110.92倍,创178天以来新低,总市值110.03亿元。 最新一期业绩显示,2025年一季报,公司实现营业收入3.30亿元,同比2.35%;净利润2863.67万元,同 比-32.97%,销售毛利率76.76%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13福瑞股份110.9297.136.17110.03亿行业平均 53.4748.944.65111.37亿行业中值37.0037.172.5551.30亿1九安医疗10.9711.100.86185.21亿2英科医疗 13.1414.171.17207.60亿3新华医疗15.4114.281.2698.77亿4振德医疗15.6614.761.0056.83亿5山东药玻 15.9115.961.83150.51亿6奥美医疗16.0415.721.6557.94亿7康德莱16.7616.781.3936.12亿8奥泰生物 17.0017.931.3754.22亿9九强生物17.1215.922.1084.78亿10维力医疗17. ...
最新!福瑞股份2025年半年度业绩预告
思宇MedTech· 2025-07-21 10:03
Core Viewpoint - The company, Furui Co., Ltd. (stock code: 300049), is forecasting a significant decline in net profit for the first half of 2025 compared to the same period in 2024, with expected profits ranging from 50 million to 60 million yuan, representing a year-on-year decrease of 20% to 34% [2]. Group 1: Financial Performance - The net profit attributable to shareholders is projected to be between 50 million and 60 million yuan, down from 75.36 million yuan in the same period last year, indicating a decline of 20% to 34% [2]. - The net profit after deducting non-recurring gains and losses is expected to be between 51.5 million and 61.5 million yuan, compared to 74.46 million yuan in the previous year, reflecting a decrease of 17% to 31% [2]. - The company anticipates a net profit of approximately 75 million to 85 million yuan after excluding the impact of stock incentive expenses and exchange losses, which would represent a year-on-year growth of about 5% to 19% [7]. Group 2: Business Overview - Furui Co., Ltd. specializes in the research, development, production, and sales of medical devices and treatments for liver diseases, with a focus on the compound tortoise shell soft liver tablet, the first anti-liver fibrosis drug approved by the National Medical Products Administration [4][5]. - The company reported a revenue of 283 million yuan from its proprietary drug business in 2024, marking a year-on-year increase of 44.31% [5]. - The medical device segment has shown growth, with sales revenue expected to be between 470 million and 490 million yuan, reflecting an increase of approximately 11% to 16% compared to the previous year [7]. Group 3: Development and Services - The company has developed and sells the FibroScan series of liver fibrosis diagnostic instruments and the FibroMeter series of blood testing analysis tools, which are recognized for their innovative non-invasive detection technology [8]. - Furui Co., Ltd. provides chronic disease management services for liver disease patients through its internet hospital, establishing a comprehensive and personalized healthcare management platform [8]. - The company is also involved in software development, IT consulting services, and real estate operations, diversifying its business portfolio [8].
7.50亿主力资金净流入,医药电商概念涨2.00%
Zheng Quan Shi Bao Wang· 2025-07-16 09:03
截至7月16日收盘,医药电商概念上涨2.00%,位居概念板块涨幅第8,板块内,124股上涨,润都股 份、奥赛康、万邦德等涨停,福瑞股份、莱美药业、回盛生物等涨幅居前,分别上涨9.55%、8.48%、 5.54%。跌幅居前的有沃华医药、恩威医药、天宇股份等,分别下跌4.02%、3.01%、2.42%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅(%) | 概念 | 今日涨跌幅(%) | | --- | --- | --- | --- | | 动物疫苗 | 2.91 | 金属铅 | -1.27 | | 仿制药一致性评价 | 2.67 | 硅能源 | -1.22 | | 青蒿素 | 2.65 | 金属锌 | -1.18 | | 禽流感 | 2.33 | 稀土永磁 | -0.85 | | 阿尔茨海默概念 | 2.28 | 特钢概念 | -0.81 | | 海南自贸区 | 2.21 | PET铜箔 | -0.73 | | 肝炎概念 | 2.17 | PCB概念 | -0.72 | | 医药电商 | 2.00 | AI手机 | -0.70 | | 幽门螺杆菌概念 | 1.93 | 金属铜 | -0.67 | | ...
肝炎概念涨2.17%,主力资金净流入这些股
Zheng Quan Shi Bao Wang· 2025-07-16 09:02
截至7月16日收盘,肝炎概念上涨2.17%,位居概念板块涨幅第7,板块内,120股上涨,润都股份、万 邦德、力生制药等涨停,广生堂、福瑞股份、莱美药业等涨幅居前,分别上涨16.55%、9.55%、 8.48%。跌幅居前的有之江生物、*ST苏吴、微芯生物等,分别下跌6.08%、5.02%、2.71%。 今日涨跌幅居前的概念板块 | 603882 | 金域医 | 0.34 | 2.48 | 1840.31 | 5.55 | | --- | --- | --- | --- | --- | --- | | | 学 | | | | | | 002038 | 双鹭药 | 2.00 | 2.59 | 1834.82 | 10.96 | | | 业 | | | | | | 000766 | 通化金 马 | 1.29 | 2.13 | 1802.62 | 3.62 | | 300233 | 金城医 药 | 4.28 | 9.32 | 1763.81 | 2.97 | | 688321 | 微芯生 物 | -2.71 | 4.66 | 1763.67 | 2.69 | | 300194 | 福安药 业 | 2.95 | 5.29 ...
【盘中播报】50只个股跨越牛熊分界线
Zheng Quan Shi Bao Wang· 2025-07-16 03:14
证券时报·数据宝统计,截至今日上午10:29,上证综指3500.42点,收于年线之上,涨跌幅为-0.13%,A 股总成交额为6749.60亿元。到目前为止,今日有50只A股价格突破了年线,其中乖离率较大的个股有福 瑞股份、海德股份、田野股份等,乖离率分别为5.83%、4.84%、3.71%;万盛股份、鸿利智汇、汉钟精 机等个股乖离率较小,刚刚站上年线。 7月16日突破年线个股乖离率排名 (文章来源:证券时报网) | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | (%) | (%) | (元) | (元) | (%) | | 300049 | 福瑞股 份 | 7.83 | 4.06 | 37.23 | 39.40 | 5.83 | | 000567 | 海德股 份 | 7.77 | 2.59 | 6.22 | 6.52 | 4.84 | | 832023 | 田野股 份 | 6.35 | 5.38 | 4.52 | 4.69 | 3.71 | | 688695 ...
福瑞股份(300049) - 2025 Q2 - 季度业绩预告
2025-07-14 09:20
证券代码:300049 证券简称:福瑞股份 公告编号:2025-028 内蒙古福瑞医疗科技股份有限公司 三、业绩变动原因说明 报告期内,公司业绩变动的主要原因: 1、报告期内,医疗器械业务持续拓展,销售收入与利润较上年同期实现增长。整体 实现营业收入约 4.7-4.9 亿元,较上年同期增长约 11%-16%,整体实现净利润约 0.73-0.78 亿元,对归属于上市公司股东的净利润影响为 0.37-0.39 亿元。 2025 年半年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导 性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间:2025 年 1 月 1 日至 2025 年 6 月 30 日 2、预计的业绩:收入上升利润下降 | 目 项 | 本报告期 | | 上年同期 | | --- | --- | --- | --- | | | (2025 年上半年) | | (2024 年上半年) | | 归属于上市公司 | 盈利:5,000.00 万元—6,000.00 | 万元 | 盈利:7,536.40 | | 股东的净利润 | 比上年同期下降:34% — | 20% ...
华创医药周观点:中药企业的创新布局2025/07/12
华创医药组公众平台· 2025-07-12 07:05
Market Review - The CITIC Pharmaceutical Index increased by 1.80%, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 CITIC first-level industry indices [5] - The top ten stocks by increase this week include Frontier Biologics-U, Medici, Lianhuan Pharmaceutical, Kangchen Pharmaceutical, and others, with Frontier Biologics-U leading at 41.43% [4][5] - The bottom ten stocks by decrease include ST Weiming, Shenzhou Cell, and Shuotai Shen, with ST Weiming dropping by 18.51% [4][5] Overall Viewpoint and Investment Themes - The current valuation of the pharmaceutical sector is at a low point, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company remains optimistic about the growth of the pharmaceutical industry by 2025, driven by macroeconomic factors and the demand from major categories [9] - In the innovative drug sector, there is a shift from quantity logic to quality logic, focusing on differentiated domestic and international pipelines. The company suggests paying more attention to products and companies that can ultimately realize profits [9] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and the home medical device market is expected to benefit from subsidy policies. The company highlights the potential for import substitution and growth in the orthopedic sector post-collection [9] - The innovation chain (CXO + life sciences services) is expected to see a rebound in overseas investment and a bottoming out in domestic investment, with a potential return to high growth by 2025 [9] - The pharmaceutical industry is anticipated to enter a new growth cycle, with a focus on specialty raw materials and the expiration of patents leading to new growth opportunities [9] Industry and Company Events - The company highlights the innovative layout of traditional Chinese medicine enterprises, with several products in clinical II and III phases, including those targeting chronic insomnia and primary acute gouty arthritis [29][30] - Yunnan Baiyao has several drugs in various clinical stages, including those for prostate cancer and other conditions, indicating a robust pipeline [16][19] - The company emphasizes the importance of the blood products sector, which is expected to see significant growth due to relaxed approval processes and increased production capacity [14] - The innovative drug pipeline of Yiling Pharmaceutical focuses on cardiovascular, respiratory, and endocrine diseases, with multiple drugs in clinical trials [20][21]
福瑞股份(300049):MASH新药上市进程加快,看好诊断设备持续放量
Great Wall Securities· 2025-07-11 11:35
证券研究报告 | 公司动态点评 2025 年 07 月 11 日 福瑞股份(300049.SZ) MASH 新药上市进程加快,看好诊断设备持续放量 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 1,154 | 1,349 | 1,727 | 2,457 | 3,629 | | 增长率 yoy(%) | 14.4 | 16.9 | 28.0 | 42.3 | 47.7 | | 归母净利润(百万元) | 102 | 113 | 188 | 290 | 462 | | 增长率 yoy(%) | 3.8 | 11.5 | 65.8 | 54.4 | 59.4 | | ROE(%) | 9.6 | 9.2 | 12.7 | 16.9 | 21.1 | | EPS 最新摊薄(元) | 0.38 | 0.43 | 0.71 | 1.09 | 1.74 | | P/E(倍) | 98.7 | 88.5 | 53.4 | 34.6 | 21.7 | | P/B(倍) | 6 ...
福瑞股份(300049) - 300049福瑞股份投资者关系管理信息20250711
2025-07-11 10:12
证券代码:300049 证券简称:福瑞股份 内蒙古福瑞医疗科技股份有限公司投资者关系活动记录表 | 投资者关系活动 | | □特定对象调研□分析师会议 | | --- | --- | --- | | 类别 | □媒体采访√业绩说明会 | | | | □新闻发布会□路演活动 | | | | □现场参观 | | | | □其他(请文字说明其他活动内容) | | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 2025 年 7 月 日 (周五) 下午 13:30~18:00 | 11 | | 地点 | 公司通过全景网"投资者关系互动平台"(https://ir.p5w.net) | | | | 采用网络远程的方式召开业绩说明会 | | | 上市公司接待人 | 1、董事会秘书孙秀珍 | | | 员姓名 | 2、证券事务代表叶晓亮 | | | | 3、财务经理张兴宽 | | | | 投资者提出的问题及公司回复情况 | | | | 公司就投资者在本次说明会中提出的问题进行了回复: | | | | 1、公司 FibroScan 系列设备有没有和国内 MASH 药物研发企 | | | ...
福瑞股份(300049) - 关于参加内蒙古辖区上市公司2025年投资者网上集体接待日活动的公告
2025-07-09 07:42
本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导 性陈述或重大遗漏。 为进一步加强与投资者的互动交流,内蒙古福瑞医疗科技股份有限公司(以下简称 "公司")将参加由内蒙古证监局、内蒙古上市公司协会与深圳市全景网络有限公司联 合举办的"内蒙古辖区上市公司 2025 年投资者网上集体接待日活动",现将相关事项 公告如下: 本次活动将采用网络远程的方式举行,投资者可登录" 全景路演" 网站 (http://rs.p5w.net),或关注微信公众号:全景财经,或下载全景路演 APP,参与本次 互动交流,活动时间为 2025 年 7 月 11 日(周五)16:00-18:00。届时公司高管将在线就 公司 2024 年度业绩、公司治理、发展战略、经营状况、融资计划、股权激励和可持续 发展等投资者关心的问题,与投资者进行沟通与交流,欢迎广大投资者踊跃参与! 证券代码:300049 证券简称:福瑞股份 公告编号:2025-027 内蒙古福瑞医疗科技股份有限公司 关于参加内蒙古辖区上市公司 2025 年投资者 网上集体接待日活动的公告 二零二五年七月九日 特此公告。 内蒙古福瑞医疗科技股份有限公司董事 ...